Effect of 2.5 Years of Rasagiline Therapy on Progression of Cognitive Biomarkers Assessed by MRI in Parkinson's Disease.
Status:
Completed
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
In this investigator-initiated study, we will compare changes in brain cognitive biomarkers
assessed by diffusion tensor imaging over 2.5 years among 12 patients with Idiopathic
Parkinson's disease (IPD) receiving rasagiline, 20 IPD patients not receiving MAO-B
inhibitors and 25 age-matched healthy controls. Will also compare the changes in Mini-Mental
State Exam (MMSE) and Montreal Cognitive Assessment (MoCA) scores and plasma brain-derived
neurotrophic factor (BDNF) with changes in brain cognitive biomarkers in all IPD patients and
HC over 2.5 years.